• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

病例报告：通过弹性输液器联合持续输注头孢他啶-阿维巴坦和氨曲南12周，用于治疗由产金属β-内酰胺酶菌引起的骨和关节感染。

Case report: Continuous infusions of ceftazidime-avibactam and aztreonam in combination through elastomeric infusors for 12 weeks for the treatment of bone and joint infections due to metallo-β-lactamase producing .

作者信息

Merad Yanis, Conrad Anne, Brosset Sophie, Schmidt Axel, Hanriat Camille, Lustig Sebastien, Laurent Frederic, Kolenda Camille, Roussel-Gaillard Tiphaine, Batailler Cecile, Ferry Tristan

机构信息

Infectious Disease Department, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France.

Université Claude Bernard Lyon 1, Lyon, France.

出版信息

Front Med (Lausanne). 2023 Aug 3;10:1224922. doi: 10.3389/fmed.2023.1224922. eCollection 2023.

DOI:10.3389/fmed.2023.1224922
PMID:37601796
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10435880/
Abstract

Among carbapenem-resistant , metallo-beta-lactamase producing strains represent a growing therapeutic challenge. While the association of aztreonam and ceftazidime-avibactam has been investigated in recent years for the treatment of infections involving these strains, little to no clinical data support the use of this association for the treatment of bone and joint infections. We report two cases of complex bone and joint infections involving metallo-beta-lactamase-producing , successfully treated at our referral center with aztreonam and ceftazidime-avibactam for 12 weeks in continuous infusions through elastomeric infusors.

摘要

在耐碳青霉烯类细菌中，产金属β-内酰胺酶的菌株对治疗构成了越来越大的挑战。近年来，虽然已对氨曲南和头孢他啶-阿维巴坦联合用药治疗涉及这些菌株的感染进行了研究，但几乎没有临床数据支持将这种联合用药用于治疗骨和关节感染。我们报告了两例涉及产金属β-内酰胺酶细菌的复杂性骨和关节感染病例，在我们的转诊中心通过弹性输液器持续输注氨曲南和头孢他啶-阿维巴坦，成功治疗了12周。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dd7/10435880/1700981dfebb/fmed-10-1224922-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dd7/10435880/ab866b55c1ab/fmed-10-1224922-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dd7/10435880/1700981dfebb/fmed-10-1224922-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dd7/10435880/ab866b55c1ab/fmed-10-1224922-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dd7/10435880/1700981dfebb/fmed-10-1224922-g0002.jpg

相似文献

1
Case report: Continuous infusions of ceftazidime-avibactam and aztreonam in combination through elastomeric infusors for 12 weeks for the treatment of bone and joint infections due to metallo-β-lactamase producing .病例报告：通过弹性输液器联合持续输注头孢他啶-阿维巴坦和氨曲南12周，用于治疗由产金属β-内酰胺酶菌引起的骨和关节感染。
Front Med (Lausanne). 2023 Aug 3;10:1224922. doi: 10.3389/fmed.2023.1224922. eCollection 2023.
2
Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020).头孢地尔罗与新型β-内酰胺类-β-内酰胺酶抑制剂联合制剂对产金属β-内酰胺酶革兰氏阴性杆菌的活性：一项为期两年（2019-2020 年）研究的见解。
J Chemother. 2023 May;35(3):198-204. doi: 10.1080/1120009X.2022.2090615. Epub 2022 Jun 22.
3
The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases.氨曲南与阿维巴坦联合用于治疗产金属β-内酰胺酶革兰阴性菌的研究进展：体外研究与临床病例的系统评价
Antibiotics (Basel). 2021 Aug 20;10(8):1012. doi: 10.3390/antibiotics10081012.
4
Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing in the Antibiotic Resistance Laboratory Network, March 2019 to December 2020.2019 年 3 月至 2020 年 12 月，抗生素耐药实验室网络中金属-β-内酰胺酶产生菌的阿兹仑司他-阿维巴坦药敏测试项目。
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0048621. doi: 10.1128/AAC.00486-21.
5
Activity of aztreonam in combination with ceftazidime-avibactam against serine- and metallo-β-lactamase-producing Pseudomonas aeruginosa.头孢他啶-阿维巴坦联合氨曲南对产丝氨酸和金属β-内酰胺酶铜绿假单胞菌的活性。
Diagn Microbiol Infect Dis. 2021 Jan;99(1):115227. doi: 10.1016/j.diagmicrobio.2020.115227. Epub 2020 Sep 28.
6
Evaluation of gradient strip diffusion for susceptibility testing of aztreonam-avibactam in metallo-β-lactamase-producing Enterobacterales.梯度条带扩散法评估金属β-内酰胺酶产生的肠杆菌科细菌中阿兹巴坦-阿维巴坦药敏试验。
J Clin Microbiol. 2024 Nov 13;62(11):e0064924. doi: 10.1128/jcm.00649-24. Epub 2024 Sep 30.
7
In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021.2019-2021 年 ATLAS 全球监测计划在拉丁美洲、非洲/中东、亚洲和欧亚地区收集的肠杆菌科分离株中，阿维巴坦-阿唑巴坦对其的体外活性。
Eur J Clin Microbiol Infect Dis. 2023 Sep;42(9):1135-1143. doi: 10.1007/s10096-023-04645-2. Epub 2023 Aug 1.
8
Increased zinc levels facilitate phenotypic detection of ceftazidime-avibactam resistance in metallo-β-lactamase-producing Gram-negative bacteria.锌水平升高有助于在产金属β-内酰胺酶的革兰氏阴性菌中对头孢他啶-阿维巴坦耐药性进行表型检测。
Front Microbiol. 2022 Nov 22;13:977330. doi: 10.3389/fmicb.2022.977330. eCollection 2022.
9
In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula.体外研究头孢他啶-阿维巴坦、氨曲南-阿维巴坦和其他挽救性抗生素对来自阿拉伯半岛的碳青霉烯类耐药肠杆菌科的疗效。
Int J Infect Dis. 2020 Oct;99:253-259. doi: 10.1016/j.ijid.2020.07.050. Epub 2020 Jul 29.
10
Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.氨曲南联合克拉维酸、他唑巴坦或阿维巴坦治疗产金属β-内酰胺酶革兰氏阴性菌感染。
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.00010-19. Print 2019 May.

引用本文的文献

1
Antimicrobial Treatment Options for Multidrug Resistant Gram-Negative Pathogens in Bone and Joint Infections.骨与关节感染中耐多药革兰氏阴性病原体的抗菌治疗选择
Pathogens. 2025 Feb 1;14(2):130. doi: 10.3390/pathogens14020130.
2
Comparison of testing methods assessing the in vitro efficacy of the combination of aztreonam with avibactam on multidrug-resistant Gram-negative bacilli.比较评估多药耐药革兰氏阴性杆菌中阿维巴坦与氨曲南联合体外疗效的检测方法。
Ann Clin Microbiol Antimicrob. 2024 May 25;23(1):47. doi: 10.1186/s12941-024-00708-0.

本文引用的文献

1
Last resort beta-lactam antibiotics for treatment of New-Delhi Metallo-Beta-Lactamase producing Enterobacterales and other Difficult-to-Treat Resistance in Gram-negative bacteria: A real-life study.最后手段β-内酰胺类抗生素治疗新型德里金属β-内酰胺酶产生肠杆菌科和其他革兰氏阴性菌的难治性耐药：一项真实世界研究。
Front Cell Infect Microbiol. 2022 Dec 5;12:1048633. doi: 10.3389/fcimb.2022.1048633. eCollection 2022.
2
Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020).头孢地尔罗与新型β-内酰胺类-β-内酰胺酶抑制剂联合制剂对产金属β-内酰胺酶革兰氏阴性杆菌的活性：一项为期两年（2019-2020 年）研究的见解。
J Chemother. 2023 May;35(3):198-204. doi: 10.1080/1120009X.2022.2090615. Epub 2022 Jun 22.
3
Stability Studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy.重症监护病房持续输注及门诊胃肠外抗菌治疗中16种抗生素的稳定性研究
Antibiotics (Basel). 2022 Mar 29;11(4):458. doi: 10.3390/antibiotics11040458.
4
The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases.氨曲南与阿维巴坦联合用于治疗产金属β-内酰胺酶革兰阴性菌的研究进展：体外研究与临床病例的系统评价
Antibiotics (Basel). 2021 Aug 20;10(8):1012. doi: 10.3390/antibiotics10081012.
5
activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe.铁载体头孢菌素头孢地尔对来自欧洲的经分子特征鉴定的碳青霉烯不敏感革兰氏阴性菌的活性。
JAC Antimicrob Resist. 2020 Aug 25;2(3):dlaa060. doi: 10.1093/jacamr/dlaa060. eCollection 2020 Sep.
6
Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions.碳青霉烯类耐药肠杆菌科感染的治疗：最新进展和未来方向。
Eur J Clin Microbiol Infect Dis. 2021 Oct;40(10):2053-2068. doi: 10.1007/s10096-021-04296-1. Epub 2021 Jun 24.
7
Combination of aztreonam, ceftazidime-avibactam and amikacin in the treatment of VIM-1 Pseudomonas aeruginosa ST235 osteomyelitis.联合使用氨曲南、头孢他啶-阿维巴坦和阿米卡星治疗产 VIM-1 型金属酶铜绿假单胞菌 ST235 性骨髓炎。
Int J Infect Dis. 2021 Jul;108:510-512. doi: 10.1016/j.ijid.2021.05.085. Epub 2021 Jun 4.
8
β-Lactam Allergy and Cross-Reactivity: A Clinician's Guide to Selecting an Alternative Antibiotic.β-内酰胺类过敏与交叉反应：临床医生选择替代抗生素指南
J Asthma Allergy. 2021 Jan 18;14:31-46. doi: 10.2147/JAA.S242061. eCollection 2021.
9
Treatment of invasive IMP-4 Enterobacter cloacae infection in transplant recipients using ceftazidime/avibactam with aztreonam: A case series and literature review.使用头孢他啶/阿维巴坦联合氨曲南治疗移植受者侵袭性 IMP-4 阴沟肠杆菌感染：病例系列和文献复习。
Transpl Infect Dis. 2021 Apr;23(2):e13510. doi: 10.1111/tid.13510. Epub 2020 Dec 4.
10
New β-Lactam-β-Lactamase Inhibitor Combinations.新型β-内酰胺类-β-内酰胺酶抑制剂复方制剂
Clin Microbiol Rev. 2020 Nov 11;34(1). doi: 10.1128/CMR.00115-20. Print 2020 Dec 16.